Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model
- PMID: 8851612
- PMCID: PMC163199
- DOI: 10.1128/AAC.40.3.784
Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model
Abstract
The kinetics of the postantibiotic effect (PAE) during one dosing interval of tobramycin against Staphylococcus aureus and Pseudomonas aeruginosa was investigated. We determined the PAE at different time points during this dosing interval of 12 h in an in vitro pharmacokinetic model simulating human pharmacokinetics in which the half-life of tobramycin was adjusted to 2.4 +/- 0.2 h. Using an enzymatic method to inactivate tobramycin, we determined PAEs in samples extracted from the model at 1, 5, 8, and 12 h, corresponding with tobramycin concentrations of 20, 5, 2, and 1 times the MIC for the test organism. The PAE decreased significantly from 2.5 h at 1 h to 0 h at 12 h. No change in MIC was observed for the strains during the experiments. We conclude that the PAE decreases with decreasing tobramycin concentrations during a 12-h dosing interval and completely disappears after the concentration has reached the MIC for the test organism. On the basis of these observations, the emphasis that is placed on the PAE in discussions about the optimal dosing interval in aminoglycoside therapy is questionable.
Similar articles
-
Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.Antimicrob Agents Chemother. 1998 Apr;42(4):749-54. doi: 10.1128/AAC.42.4.749. Antimicrob Agents Chemother. 1998. PMID: 9559777 Free PMC article.
-
Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model.J Antimicrob Chemother. 1998 Jul;42(1):61-5. doi: 10.1093/jac/42.1.61. J Antimicrob Chemother. 1998. PMID: 9700529
-
Postantibiotic effect and postantibiotic sub-minimum inhibitory concentration effect of valnemulin against Staphylococcus aureus isolates from swine and chickens.Lett Appl Microbiol. 2014 Feb;58(2):150-5. doi: 10.1111/lam.12168. Epub 2013 Oct 23. Lett Appl Microbiol. 2014. PMID: 24117872
-
Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro.J Antimicrob Chemother. 1994 May;33(5):937-47. doi: 10.1093/jac/33.5.937. J Antimicrob Chemother. 1994. PMID: 8089067
-
In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin.J Chemother. 1995 Aug;7(4):355-62. doi: 10.1179/joc.1995.7.4.355. J Chemother. 1995. PMID: 8568546
Cited by
-
Comparative pharmacokinetics of the carbapenems: clinical implications.Clin Pharmacokinet. 2000 Sep;39(3):185-201. doi: 10.2165/00003088-200039030-00002. Clin Pharmacokinet. 2000. PMID: 11020134 Review.
-
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.Clin Pharmacokinet. 2005;44(2):201-10. doi: 10.2165/00003088-200544020-00005. Clin Pharmacokinet. 2005. PMID: 15656698
-
Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.Antimicrob Agents Chemother. 1998 Apr;42(4):749-54. doi: 10.1128/AAC.42.4.749. Antimicrob Agents Chemother. 1998. PMID: 9559777 Free PMC article.
-
Pharmacological considerations for the proper clinical use of aminoglycosides.Drugs. 2011 Dec 3;71(17):2277-94. doi: 10.2165/11597020-000000000-00000. Drugs. 2011. PMID: 22085385 Review.
-
Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.Antimicrob Agents Chemother. 2006 Aug;50(8):2626-31. doi: 10.1128/AAC.01165-05. Antimicrob Agents Chemother. 2006. PMID: 16870751 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical